Table 1.

Characteristics of the patient cohort

	Adalimumab N = 99	Etanercept N = 83	Golimumab N = 79	Certolizumab pegol N = 12	p value
Number of men, n (%)	60 (61)	53 (64)	59 (75)	8 (67)	0.25
Age, mean (SD)	46 (11)	44 (12)	42 (11)	47 (13)	0.12
BMI	26.1 (4.6)	26.2 (4.5)	26.8 (4.7)	25.6 (3.9)	0.74
Disease duration (years), mean (SD)	15.8 (10.3)	14.8 (10.1)	10.9 (9.4)	8.8 (6.9)	< 0.001
BASDAI, mean (SD)	1.7 (1.8)	2.1 (1.8)	2.0 (1.7)	1.2 (1.2)	0.12
MASES, mean (SD)	0.4 (1.4)	0.4 (1.4)	0.4 (1.3)	0.1 (0.3)	0.057
BASFI, mean (SD)	1.5 (2.0)	2.0 (2.0)	1.6 (1.5)	1.2 (1.0)	0.24
ESR, mean (SD)	8 (8)	9 (9)	6 (6)	5 (6)	0.064
CRP, mean (SD)	3 (4)	4 (5)	3 (3)	3 (4)	0.53
HLA-B27, n (%)	87 (94)	74 (95)	69 (90)	12 (100)	0.58
Treatment duration with current medicine (months) median (IQR), range	46 (22.71) [1–126]	46 (18.71) [2–131]	17 (9.33) [2–101]	7 (3.10) [3–23]	< 0.001
Duration of all biologic treatment (months), median (IQR), range	57 (35.104) [3, 172]	55 (31.91) [2–177]	25 (16.55) [2–210]	8 (3.60) [3–110]	< 0.001
DMARD, n (%)
None	44 (44)	42 (51)	36 (46)	3 (25)	0.40
Methotrexate	41 (41)	25 (30)	32 (41)	6 (50)	0.30
Sulfasalazine	21 (21)	22 (27)	17 (22)	5 (42)	0.39
Leflunomide	1 (1)	0 (0)	0 (0)	0 (0)	0.99
Peroral glucocorticoid, n (%)	5 (5)	2 (2)	3 (4)	3 (25)	0.039
Previous biologic treatment
Number, n (%)					0.69
0	56 (57)	50 (60)	43 (54)	8 (67)
1	36 (36)	24 (29)	21 (27)	2 (17)
2	6 (6)	5 (6)	11 (14)	2 (17)
3–4	1 (1)	4 (5)	4 (5)	0 (0)
Previous biologic treatment
Certolizumab pegol	2 (2)	3 (4)	2 (3)	.
Etanercept	29 (29)	.	17 (22)	1 (8)
Adalimumab	.	25 (30)	22 (28)	2 (17)
Golimumab	5 (5)	7 (8)	.	2 (17)
Infliximab	12 (12)	6 (7)	14 (18)	1 (8)

BMI body mass index, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, MASES Maastricht Enthesitis Score, BASFI Bath Ankylosing Spondylitis Functional Index, ESR erythrocyte sedimentation rate, CRP C-reactive protein, HLA-B27 human leukocyte antigen B27, DMARD disease-modifying antirheumatic drug